Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | NAE1 | Q13564 | 2/20 | 0.49 |
| ▸ | GRK5 | P34947 | 1/20 | 0.49 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.49 |
| ▸ | UBA6 | A0AVT1 | 1/20 | 0.49 |
| ▸ | NEDD8 | Q15843 | 1/20 | 0.49 |
| ▸ | UBA3 | Q8TBC4 | 1/20 | 0.49 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.49 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.49 |
| ▸ | ATG7 | O95352 | 14/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1801570 | 1.00 | CA2 (0.49) | CA2NAE1GRK5CSNK1A1UBA6 | |
| SCHEMBL14430991 | 0.87 | ATG7 (0.53) | CA2NAE1GRK5CSNK1A1UBA6 | |
| SCHEMBL1797922 | 0.86 | CA2 (0.41) | CA2NAE1GRK5CSNK1A1UBA6 | |
| SCHEMBL17889814 | 0.86 | NAE1 (0.41) | CA2NAE1GRK5CSNK1A1UBA6 | |
| SCHEMBL1798411 | 0.86 | ADK (0.54) | — | |
| SCHEMBL25996051 | 0.86 | ADK (0.54) | — | |
| SCHEMBL27216186 | 0.81 | TYMP (0.47) | — | |
| SCHEMBL18490419 | 0.81 | TYMP (0.47) | — | |
| SCHEMBL22034033 | 0.81 | TYMP (0.47) | — | |
| SCHEMBL192451 | 0.80 | NAE1 (0.76) | CA2NAE1GRK5CSNK1A1UBA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | CA2 3826/4885NAE1 41/4885GRK5 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.